http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2574580-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-12 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 |
| filingDate | 2004-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b07ba79f85f967da025030bdaf1ee900 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed8146c9bd729a6e19c02b9ad0560855 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac19c3504c1eeafae3a96c835bf4f585 |
| publicationDate | 2016-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2574580-T3 |
| titleOfInvention | Non-nucleoside reverse transcriptase I inhibitors to treat HIV-mediated diseases |
| abstract | A compound according to formula I, wherein; ** Formula ** X1 is selected from the group consisting of R5O, R5S (O) n, R5CH2, R5CH2O, R5CH2S (O) n, R5OCH2, R5S (O ) nCH2 and NR5R6; X2 is selected from the group consisting of O, S, and NR7; R1 and R2 (i) are each independently selected from the group consisting of hydrogen, C1-6alkyl, haloC1-6alkyl, C3-8cycloalkyl, C1-6alkylthio, C1-6alkylsulfinyl, C1-6alkylsulfonyl, haloalkoxy C1-6, C1-6 haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano; R3 and R4 are each independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkylthio , halogen, amino, alkylamino, dialkylamino, aminoacyl, nitro and cyano; R5 is selected from the group consisting of phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyrrolyl; wherein said phenyl and said naphthyl are optionally substituted with one to three substituents independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, C 1-6 alkoxy, C 1-6 alkylthio , C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, C1-6 haloalkoxy, C1-6 haloalkylthio, halogen, amino, alkylamino, dialkylamino, aminoacyl, acyl, alkoxycarbonyl, carbamoyl, N-alkylcarbamoyl, N, N-dialkylcarbamoyl, nitro and cyano. ; R6 is hydrogen, C1-6alkyl, or acyl; R7 is hydrogen or C1-6 alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, alkoxy, thiol, alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, halogen, amino, alkylamino, dialkylamino, aminoalkyl , alkylaminoalkyl and dialkylaminoalkyl; n is an integer from 0 to 2; and acid addition salts thereof; where acyl when mentioned alone or on an aminoacyl is a radical of formula C (> = O) R where R is hydrogen, branched or unbranched alkyl containing 1 to 6 carbon atoms or a phenyl group. |
| priorityDate | 2003-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.